Fig. 8

The knock-down of PARP1 potentiates the anti-cancer effect of olaparib in osteosarcoma cells. a The knock-down of PARP1 with siRNA for PARP1 and doxorubicin significantly inhibited the growth of U2OS, SaOS2, and MG63 cells. Moreover, the knock-down of PARP1 potentiated the anti-proliferative effect of doxorubicin in osteosarcoma cells as indicated by an MTT assay. b The expression of cleaved PARP1 and BAX increased, and the expression of BCL2 decreased with co-treatment of siRNA for PARP1 and with doxorubicin as indicated by western blot analysis. *, versus control, P < 0.05; **, versus control, P < 0.001; †, versus doxorubicin, P < 0.05; ††, versus doxorubicin, P < 0.001